NVO’s Tresiba and Xultophy Could See Solid Growth in 2018
Novo Nordisk’s (NVO) Tresiba reported revenues of 1.76 billion Danish kroner in the first quarter compared to 1.49 billion Danish kroner in the first quarter of 2017, which reflected ~18.0% YoY (year-over-year) growth.